Open Access

ARTICLE

Long Noncoding RNA XIST Regulates miR-137–EZH2 Axis to Promote Tumor Metastasis in Colorectal Cancer

by

* Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P.R. China
† Department of Oncology, The Second People’s Hospital of Taizhou, Taizhou, Jiangsu Province, P.R. China
‡ Department of Oncology, Affiliated Hospital of Jiangnan University, The Fourth People’s Hospital of Wuxi, Wuxi, Jiangsu, P.R. China

Oncology Research 2019, 27(1), 99-106. https://doi.org/10.3727/096504018X15195193936573

Retracted 17 July 2024

Abstract

We aimed to investigate the significant role of long noncoding RNA X inactive specific transcript (XIST) in regulating tumor metastasis in colorectal cancer (CRC), as well as its possible mechanism. Expression of lncRNA XIST in CRC tissues and CRC cells was detected. CRC cells were transfected with pc-XIST, blank control si-XIST, or si-control, and then the effects of lncRNA XIST on CRC cell migration and invasion were investigated, along with the interaction between lncRNA XIST and miR-137. lncRNA XIST was upregulated in CRC tissues. Compared with HT29 cells that had low metastatic potential, XIST was markedly more highly expressed in LoVo cells that had a higher metastatic potential. Overexpression of XIST promoted the migratory and invasive potential of HT29 cells, while knockdown of XIST inhibited the migratory and invasive potential of LoVo cells. Moreover, epithelial–mesenchymal transition (EMT) markers, including E-cadherin, N-cadherin, and vimentin, exhibited corresponding expression changes. In addition, miR-137 was inhibited by XIST, and inhibition of miR-137 could reverse the effects of knockdown of XIST on the migratory and invasive potential of LoVo cells. Furthermore, enhancer of zeste homolog 2 (EZH2) was confirmed as a target of miR- 137. Our data reveal that lncRNA XIST may promote tumor metastasis in CRC possibly through regulating the miR-137–EZH2 axis. lncRNA XIST may serve as a prognostic indicator for CRC progression.

---

Keywords

---